Pregled bibliografske jedinice broj: 1252212
Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications
Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications // Journal of Pediatric Gastroenterology & ; Nutrition, 76 (2022), 2; 232-247 doi:10.1097/mpg.0000000000003633 (međunarodna recenzija, članak, stručni)
CROSBI ID: 1252212 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Probiotics for the Management of Pediatric
Gastrointestinal Disorders: Position Paper of the
ESPGHAN Special Interest Group on Gut Microbiota
and Modifications
Autori
Szajewska, Hania ; Berni Canani, Roberto ; Domellöf, Magnus ; Guarino, Alfredo ; Hojsak, Iva ; Indrio, Flavia ; Lo Vecchio, Andrea ; Mihatsch, Walter A. ; Mosca, Alexis ; Orel, Rok ; Salvatore, Silvia ; Shamir, Raanan ; van den Akker, Chris H. P. ; van Goudoever, Johannes B. ; Vandenplas, Yvan ; Weizman, Zvi
Kolaboracija
ESPGHAN Special Interest Group on Gut Microbiota and Modifications
Izvornik
Journal of Pediatric Gastroenterology & ; Nutrition (0277-2116) 76
(2022), 2;
232-247
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
probiotics
Sažetak
Background: Probiotics, defined as live microorganisms that, when administered in adequate amounts, confer a health benefit on the host, are widely used despite uncertainty regarding their efficacy and discordant recommendations about their use. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Special Interest Group on Gut Microbiota and Modifications provides updated recommendations for the use of probiotics for the management of selected pediatric gastrointestinal disorders. Methods: All systematic reviews and/or meta- analyses, as well as subsequently published randomized controlled trials (RCTs) (until December 2021), that compared the use of probiotics in all delivery vehicles and formulations, at any dose, with no probiotic (ie, placebo or no treatment), were eligible for inclusion. The recommendations were formulated only if at least 2 RCTs on a similar well-defined probiotic strain were available. The modified Delphi process was used to establish consensus on the recommendations. Results: Recommendations for the use of specific probiotic strains were made for the management of acute gastroenteritis, prevention of antibiotic- associated diarrhea, nosocomial diarrhea and necrotizing enterocolitis, management of Helicobacter pylori infection, and management of functional abdominal pain disorders and infant colic. Conclusions: Despite evidence to support the use of specific probiotics in some clinical situations, further studies confirming the effect(s) and defining the type, dose, and timing of probiotics are still often required. The use of probiotics with no documented health benefits should be discouraged.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Medicinski fakultet, Osijek,
Klinika za dječje bolesti
Profili:
Iva Hojsak
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE